Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction

Karlsson, Jan‐Erik; El-Saadi, W; Ateş, Mustafa; Puskar, Werner; Skogvard, P; Engvall, Jan; Andersson, Rolf G. G.; Maret, Eva; Jynge, Per

doi:10.1093/ehjcvp/pvu021

Cited by 19 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To this end, note that the Mn 2þ injectate TeslaScan is a manganese-based contrast agent previously approved over a decade ago as safe and effective for use in humans by the Food and Drug Administration (FDA) (Karlsson et al, 2015;Tofts et al, 2010;Torres et al, 1997). Teslascan was originally investigated as a blood pool contrast agent to identify the tumor burden in the liver.…”

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

“…Teslascan was originally investigated as a blood pool contrast agent to identify the tumor burden in the liver. Teslascan has shown to lack adverse events, even in patients with cancer and patients that needed cardiac reperfusion (Karlsson et al, 2015). Teslascan is converted in vivo into the lipid soluble Mn dipyridoxyl ethyldiamine (Karlsson et al, 2015).…”

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

“…Teslascan has shown to lack adverse events, even in patients with cancer and patients that needed cardiac reperfusion (Karlsson et al, 2015). Teslascan is converted in vivo into the lipid soluble Mn dipyridoxyl ethyldiamine (Karlsson et al, 2015). In addition to not showing toxicity, Teslascan and its metabolite act as anti-oxidants because they are superoxide dismutase mimetics, and have ironbinding abilities in vitro (Karlsson et al, 2015).…”

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

“…Teslascan is converted in vivo into the lipid soluble Mn dipyridoxyl ethyldiamine (Karlsson et al, 2015). In addition to not showing toxicity, Teslascan and its metabolite act as anti-oxidants because they are superoxide dismutase mimetics, and have ironbinding abilities in vitro (Karlsson et al, 2015). Preclinical and early clinical studies confirm their beneficial protection against oxidative stress in different tissues (Karlsson et al, 2015).…”

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

“…In addition to not showing toxicity, Teslascan and its metabolite act as anti-oxidants because they are superoxide dismutase mimetics, and have ironbinding abilities in vitro (Karlsson et al, 2015). Preclinical and early clinical studies confirm their beneficial protection against oxidative stress in different tissues (Karlsson et al, 2015). To determine if the low concentration of chelated manganese in Teslascan would be useful in functional studies, it was observed that the Mn 2þ in Teslascan is taken up by the rat retina in a stimulus-dependent manner Tofts et al, 2010).…”

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

See 4 more Smart Citations

MRI of rod cell compartment-specific function in disease and treatment in vivo

Berkowitz

Bissig

Roberts

2016

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

Rod cell oxidative stress is a major pathogenic factor in retinal disease, such as diabetic retinopathy (DR) and retinitis pigmentosa (RP). Personalized, non-destructive, and targeted treatment for these diseases remains elusive since current imaging methods cannot analytically measure treatment efficacy against rod cell compartment-specific oxidative stress in vivo. Over the last decade, novel MRI-based approaches that address this technology gap have been developed. This review summarizes progress in the development of MRI since 2006 that enables earlier evaluation of the impact of disease on rod cell compartment-specific function and the efficacy of anti-oxidant treatment than is currently possible with other methods. Most of the new assays of rod cell compartment-specific function are based on endogenous contrast mechanisms, and this is expected to facilitate their translation into patients with DR and RP, and other oxidative stress-based retinal diseases.

show abstract

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

Section: Addressing Concerns About Memri and Mrimentioning

confidence: 99%

See 3 more Smart Citations

MRI of rod cell compartment-specific function in disease and treatment in vivo

Berkowitz

Bissig

Roberts

2016

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

show abstract

Potential Therapeutic Applications of MnSODs and SOD‐Mimetics

Bonetta

2017

Chemistry A European J

View full text Add to dashboard Cite

Natural as well as synthetic antioxidants are constantly being investigated for their efficiency in combatting the effects of oxidative stress, which appears to be the responsible cause of several diseases, including cancer, central nervous system disorders, ischaemia-reperfusion disorders, cardiovascular conditions, and diabetes. Superoxide dismutases (SODs) constitute the ubiquitous antioxidant defences against oxidative stress that underlies numerous pathological conditions. Therefore, the development of therapeutics aimed at either delivering MnSOD more effectively to target tissues in the body in the form of MnSOD gene therapy, or the synthesis of molecules that mimic the activity of superoxide dismutase is constantly being explored. Classes that have been developed as SOD mimetics include the Mn-metalloporphyrins, Mn-cyclic polyamines, Mn-salen complexes, MnPLED derivatives as well as the nitroxides. Thus far, SOD mimetics have shown remarkable efficacy in several animal models suffering from oxidative stress injuries. A promising approach for the future of SOD and SOD mimic therapeutics appears to involve combination treatment of the antioxidants with radiotherapy or chemotherapy.

show abstract